Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses - Wikidata - wikimedia - TriplyDB

Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses

Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses

http://www.wikidata.org/entity/Q24678759

about

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1 Tumor neoantigens: building a framework for personalized cancer immunotherapy Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.Molecular characterization of virus-induced autoantibody responses.Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells.Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses Oral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses.Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients.LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity.NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity.Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant Lack of ADAM2, CALR3 and SAGE1 Cancer/Testis Antigen Expression in Lung and Breast Cancer.Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.Tumor vaccines for breast cancer Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.Anti-tumor antibodies in ovarian cancer.Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer.Cancer testis antigens--their importance in immunotherapy and in the early detection of cancer.Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.Prevalence of antitumor antibodies in laying hen model of human ovarian cancer Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer.IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation.

P2860

Q24633445-63167B67-EF57-4EF6-B5F9-61827F13EE84 Q28082704-C1ADC064-68B2-4BB1-A31F-DC0A6927E5A1 Q28648164-F1F040DF-5DB0-46DF-A92C-E433532BDF62 Q30584571-C46D8F39-743F-474E-940E-4BB1F1D6B399 Q31110185-231A3BC2-AB17-453F-9DEB-01846305B28B Q33195347-A4D84769-C92D-49B9-A953-208C3EF689CA Q33298687-9D1BF5D7-C854-40F2-B614-D0B932E57FF4 Q33909195-D358050E-5545-45D8-8EF4-5B44DED41A5B Q33999909-D0978FC2-6A23-47CD-9EFB-DC080324268D Q34034978-56125E4E-3941-4B0F-B029-9F051E5232EA Q34111719-A2C17BD5-88AB-42B8-A9D8-242DEA7DEE11 Q34111757-6565EB03-769C-4E47-A440-B64F6880E2FE Q34111830-927191FB-80D7-4EC5-A991-3FF4C7DA7B23 Q34325790-4B3D6107-432B-4713-989D-587B7109017A Q34388367-A9E43D11-5DD3-49AE-BFD8-1BA7CDAF900B Q34691545-BDAA4952-3A4C-4691-8DB5-71CACA1C18C1 Q34795354-0FF5EC85-68EF-4462-A800-5B2967452986 Q35039508-45DB2E99-C8AB-4A91-8E6E-D62005A9EDA6 Q35110486-1AEF3F70-D6E0-4FDE-901A-E308F40C513A Q35289145-42480E96-F098-4258-AB00-44702DEA86D1 Q35319290-A875E5AF-9DEA-40E1-B9AF-3E4D1CC3815D Q35739798-820152C4-6681-43A8-8DB6-7524DEA86D63 Q35921697-F78497F5-B0CD-4CAC-B5E6-4F33C6B1FEAB Q36204803-E1DC68FD-9A5B-4BA4-BB9C-3BBB5DA7D188 Q36214731-C8396DF1-546C-4D3E-820E-6651FC414E31 Q36232263-0D312208-4E6B-4206-96D7-9AC4190D8ADB Q36286948-B8223328-4EDC-431D-9140-AEE56E3159DF Q36327142-01D364BB-C0F1-42E8-93AD-FC4742CE2624 Q36382255-5FD34BC6-5006-4542-B2EC-534AB1F6E4A7 Q36425935-E1AD0F78-68F5-4BBF-A51C-D4EABEE89C34 Q36446446-9A9F80D4-2942-4D15-B821-BC6E26318D5B Q36693344-8A0440D2-B2EF-4322-897D-3F2E2CF6EB3D Q36716591-2AD94F5D-5B5E-4212-9804-234B0D7D146C Q36986730-AC587D42-C9B6-4F59-A4F9-2DBF5A0B4367 Q37001399-84A592FF-CB3F-47AE-8335-F848DAB69730 Q37012876-BAE9E7B2-73ED-425A-AB19-29E52E1B0B5E Q37040436-5D1EEA86-434F-4BCD-B921-F4E34DD36B12 Q37436255-07911FA8-5EF4-4D0E-8EF1-E538A6E633C7 Q37480057-953A7B16-3ED4-4199-8DCC-2D3C4273B711 Q37569023-FEFE677A-DFC6-49A7-8355-5D4418271F40

P2860

Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses

http://www.wikidata.org/entity/Q24678759

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Survey of naturally occurring ...... lation with antibody responses

@ast

Survey of naturally occurring ...... lation with antibody responses

@en

Survey of naturally occurring ...... lation with antibody responses

@nl

type

label

Survey of naturally occurring ...... lation with antibody responses

@ast

Survey of naturally occurring ...... lation with antibody responses

@en

Survey of naturally occurring ...... lation with antibody responses

@nl

prefLabel

Survey of naturally occurring ...... lation with antibody responses

@ast

Survey of naturally occurring ...... lation with antibody responses

@en

Survey of naturally occurring ...... lation with antibody responses

@nl

P1433

Q24678759-C42F26C9-8418-4FB8-A558-2C745AC36BBA

P1476

Q24678759-7C5D6B19-514C-41F8-8A86-666841E3699F

P2093

Q24678759-229600FC-52A4-437D-9732-E55DBA6B5C2C

Q24678759-36A3DDB6-E4BD-45F4-A326-EA8462236D2C

Q24678759-49417DB8-FDA5-4908-9131-C09D81E31A87

Q24678759-5B004C24-6BDF-49C5-9032-3C89E7B3BF70

Q24678759-7CD92A67-E000-45D9-9FDB-C2504ACEBCB2

Q24678759-89E41D8C-2A6E-4801-BAA9-A92D3F633C9C

Q24678759-8AB89270-480E-4D48-AC82-11AE7B141CB2

Q24678759-AD66DF35-8D2A-4426-8E59-B9F33D7770EF

Q24678759-AD819AEE-F549-41EC-A1AB-608A7119247C

Q24678759-BE09A0F6-7A66-4141-93D7-CB93CBB8140D

P2860

Q24678759-0C722DBB-B347-426A-9F17-E57FF5B34B40

Q24678759-217051EC-74E1-407D-90F6-2FBC86037363

Q24678759-2E10EC3E-5A68-46D1-97BC-BA5DD5C6C863

Q24678759-3480CF8B-A91A-4A12-9B60-A799A3427C14

Q24678759-39E79515-5AF2-456A-8919-4859A5C75087

Q24678759-441B4FE7-35AF-4D5B-8973-4106C1AD1910

Q24678759-45FD4E01-14D5-428A-B2BE-4CD793C895A5

Q24678759-4A325E0C-0F33-45BC-A0E0-3E1E66475D89

Q24678759-54AF0E11-D1E1-4B9F-82F9-7C04310030BE

Q24678759-5C6F358D-B163-4E25-9233-82BC2DEC1A02

P304

Q24678759-47C5CA64-2ED3-4C88-9DD9-0881D6478922

P31

Q24678759-1008B600-9B1B-4794-83CF-2A5FE0FA6EAB

P356

Q24678759-68A033DE-FEC0-4338-9153-44012432562A

P407

Q24678759-275C4E35-CD87-43A9-A8E8-BA398C5BDF70

P433

Q24678759-6B3D9F66-5CD4-4D39-BE5B-96A2C018C42B

P478

Q24678759-E93A7641-AAC2-4F29-A555-E37D37B647BF

P577

Q24678759-37FC92D5-AEBB-420E-87E7-E79385FCE894

P5875

Q24678759-50A31CBF-F1CD-4415-AF2E-1D5B7031B40B

P698

Q24678759-53F19C48-D0DC-4876-A6D8-5F9B63E975F7

P921

Q24678759-80D08FB9-FF3B-462D-8B7B-45F05A248009

P932

Q24678759-F79B6B1E-C32D-4FB8-BD29-0DCB1A20EB5B

P356

PNAS.1133324100

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Survey of naturally occurring ...... lation with antibody responses

@en

P2093

Alexander Knuth

http://www.w3.org/2001/XMLSchema#string

Annamalai Selvakumar

http://www.w3.org/2001/XMLSchema#string

Bo Dupont

http://www.w3.org/2001/XMLSchema#string

Djordje Atanackovic

http://www.w3.org/2001/XMLSchema#string

Elke Jäger

http://www.w3.org/2001/XMLSchema#string

Gerd Ritter

http://www.w3.org/2001/XMLSchema#string

Lloyd J Old

http://www.w3.org/2001/XMLSchema#string

Mitsutoshi Matsuo

http://www.w3.org/2001/XMLSchema#string

Nasser K Altorki

http://www.w3.org/2001/XMLSchema#string

Robert G Maki

http://www.w3.org/2001/XMLSchema#string

P2860

Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations.

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells

ICOS is critical for CD40-mediated antibody class switching

Protection against a lethal avian influenza A virus in a mammalian system.

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.

Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses.

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.

Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions.

P304

8862-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1133324100

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2003-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10667470

http://www.w3.org/2001/XMLSchema#string

P698

12853579

http://www.w3.org/2001/XMLSchema#string

P921

P932

166404

http://www.w3.org/2001/XMLSchema#string